Why Alnylam Pharmaceuticals Stock Slipped Today

Alnylam reported Q4/full-year 2025 results showing revenue nearly doubled year-over-year to just under $1.1 billion, while adjusted net income increased to roughly $169.8 million ($1.25 per share), edging past the $1.19 non-GAAP EPS consensus but missing a $1.15 billion revenue forecast. Amvuttra drove the top line, accounting for 83% of net product revenue after gaining an FDA indication for ATTR-CM in March 2025; the company guided 2026 revenue to $5.3–$5.8 billion (consensus $5.55 billion) but provided no net-income guidance, prompting a >4% stock decline on investor disappointment despite strong product uptake.

Analysis

Market structure: Alnylam (ALNY) is transitioning from a diversified RNAi developer to a commercially-driven company where Amvuttra now accounts for ~83% of net product revenue; that concentration increases ALNY’s pricing power in ATTR-CM but also raises single-product demand risk. Payers and large hospital systems will become marginal price setters — strong uptake supports revenue guidance $5.3–$5.8B for 2026, but any reimbursement pushback or supply constraints would quickly compress realized pricing and volumes.

Risk assessment: Near-term (days–weeks) risk is sentiment and IV repricing; medium-term (quarters) risks are reimbursement negotiations, manufacturing bottlenecks, or adverse safety/regulatory events that could erase >20% of quarterly revenue. Tail risks include a negative real-world safety signal or a competitor RNAi/ASO label that materially reduces Amvuttra uptake (low probability, high impact). Hidden dependency: revenue trajectory is tightly coupled to clinician adoption curves and payer reimbursement timing — monitor new patient starts and payer coverage breadth as leading indicators.

Trade implications: Tactical long exposure to ALNY is attractive on any post-earnings weakness because guidance midpoint equals consensus; consider size-limited exposure (2–4% notional) and hedge sector beta via short IBB. Use options to define risk: 6–9 month calendar or vertical call spreads capture continued adoption while limiting premium outlay; sell covered calls if you establish larger equity positions to harvest elevated IV.

Contrarian angles: The market punished a small revenue miss despite beat on adjusted EPS — consensus is underweight concentration risk but may be overly pessimistic on upside from ATTR-CM label expansion. If quarterly Amvuttra growth stays >15% QoQ for two consecutive quarters, the stock likely re-rates higher; conversely, a single-quarter growth <5% QoQ should trigger reassessment.

Key Decisions for Investors

• Establish a 2–3% long position in ALNY on any further pullback of 5–10% from current levels; thesis: 2026 guidance midpoint ($5.55B) supports upside if Amvuttra growth continues. Set tactical stop-loss at -12% from entry or if reported Amvuttra net sales decline QoQ by >10%.
• Buy a defined-risk options spread: ALNY 6–9 month call debit spread (e.g., buy ATM, sell 20–30% OTM) sized to equal a 1–2% notional exposure to limit downside while participating in upside from continued uptake and re-rating.
• Implement a pair trade: long ALNY (1% notional) vs short IBB (0.5–0.7% notional) to neutralize biotech beta and isolate idiosyncratic Amvuttra adoption; rebalance after two quarterly reports or if ALNY out-/underperforms IBB by >15%.
• Monitor three high-frequency indicators over the next 30–90 days before adding conviction: monthly new patient starts, payer coverage breadth updates, and sequential QoQ Amvuttra net sales growth. Exit or reduce exposure if payer coverage stalls or QoQ growth <5%.